Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18480
Country/Region: South Africa
Year: 2018
Main Partner: Foundation for Professional Development
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $4,482,725 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $287,325
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $269,633
Care: Pediatric Care and Support (PDCS) $74,100
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $1,658,656
Sexual Prevention: Other Sexual Prevention (HVOP) $819,372
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $344,438
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $78,000
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $877,101
Treatment: Pediatric Treatment (PDTX) $74,100
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST 25-29, Female, Negative 2019 3,447
HTS_TST 25-29, Female, Negative 2019 2,594
HTS_TST 25-29, Female, Negative 2019 770
HTS_TST 25-29, Male, Negative 2019 1,730
HTS_TST 25-29, Male, Negative 2019 2,581
HTS_TST 25-29, Male, Negative 2019 411
HTS_TST 30-34, Female, Negative 2019 5,043
HTS_TST 30-34, Female, Negative 2019 3,071
HTS_TST 30-34, Female, Negative 2019 645
HTS_TST 30-34, Male, Negative 2019 5,718
HTS_TST 30-34, Male, Negative 2019 3,352
HTS_TST 30-34, Male, Negative 2019 1,850
HTS_TST 35-39, Female, Negative 2019 5,381
HTS_TST 35-39, Female, Negative 2019 3,709
HTS_TST 35-39, Female, Negative 2019 195
HTS_TST 35-39, Male, Negative 2019 4,669
HTS_TST 35-39, Male, Negative 2019 4,086
HTS_TST 35-39, Male, Negative 2019 1,605
HTS_TST 40-49, Female, Negative 2019 3,008
HTS_TST 40-49, Female, Negative 2019 3,305
HTS_TST 40-49, Male, Negative 2019 3,469
HTS_TST 40-49, Male, Negative 2019 4,455
HTS_TST By Key Population: PWID, Negative 2019 4,707
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 115,613
HTS_TST Service Delivery Point (Community) Index Mod: 1-9, Negative 2019 1,551
HTS_TST Service Delivery Point (Community) Index Mod: 10-14, Female, Negative 2019 399
HTS_TST Service Delivery Point (Community) Index Mod: 10-14, Male, Negative 2019 399
HTS_TST Service Delivery Point (Community) Index Mod: 15-19, Female, Negative 2019 834
HTS_TST Service Delivery Point (Community) Index Mod: 15-19, Male, Negative 2019 578
HTS_TST Service Delivery Point (Community) Index Mod: 20-24, Female, Negative 2019 1,587
HTS_TST Service Delivery Point (Community) Index Mod: 20-24, Male, Negative 2019 858
HTS_TST Service Delivery Point (Community) Index Mod: 50+, Female, Negative 2019 2,425
HTS_TST Service Delivery Point (Community) Index Mod: 50+, Male, Negative 2019 4,182
HTS_TST Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative 2019 1,801
HTS_TST Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative 2019 1,801
HTS_TST Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative 2019 1,211
HTS_TST Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative 2019 472
HTS_TST Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative 2019 4,231
HTS_TST Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative 2019 1,216
HTS_TST Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative 2019 4,765
HTS_TST Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative 2019 7,122
HTS_TST Service Delivery Point (Community) Other: 15-19, Male, Negative 2019 366
HTS_TST Service Delivery Point (Community) Other: 20-24, Female, Negative 2019 1,594
HTS_TST Service Delivery Point (Community) Other: 20-24, Male, Negative 2019 1,223
HTS_TST_POS 25-29, Female, Positive 2019 208
HTS_TST_POS 25-29, Female, Positive 2019 458
HTS_TST_POS 25-29, Female, Positive 2019 131
HTS_TST_POS 25-29, Male, Positive 2019 115
HTS_TST_POS 25-29, Male, Positive 2019 455
HTS_TST_POS 25-29, Male, Positive 2019 80
HTS_TST_POS 30-34, Female, Positive 2019 311
HTS_TST_POS 30-34, Female, Positive 2019 542
HTS_TST_POS 30-34, Female, Positive 2019 104
HTS_TST_POS 30-34, Male, Positive 2019 346
HTS_TST_POS 30-34, Male, Positive 2019 591
HTS_TST_POS 30-34, Male, Positive 2019 444
HTS_TST_POS 35-39, Female, Positive 2019 331
HTS_TST_POS 35-39, Female, Positive 2019 655
HTS_TST_POS 35-39, Male, Positive 2019 302
HTS_TST_POS 35-39, Male, Positive 2019 722
HTS_TST_POS 35-39, Male, Positive 2019 400
HTS_TST_POS 40-49, Female, Positive 2019 208
HTS_TST_POS 40-49, Female, Positive 2019 583
HTS_TST_POS 40-49, Male, Positive 2019 277
HTS_TST_POS 40-49, Male, Positive 2019 786
HTS_TST_POS By Key Population: PWID, Positive 2019 1,177
HTS_TST_POS Service Delivery Point (Community) Index Mod: 1-9, Positive 2019 36
HTS_TST_POS Service Delivery Point (Community) Index Mod: 10-14, Female, Positive 2019 21
HTS_TST_POS Service Delivery Point (Community) Index Mod: 10-14, Male, Positive 2019 17
HTS_TST_POS Service Delivery Point (Community) Index Mod: 15-19, Female, Positive 2019 147
HTS_TST_POS Service Delivery Point (Community) Index Mod: 15-19, Male, Positive 2019 102
HTS_TST_POS Service Delivery Point (Community) Index Mod: 20-24, Female, Positive 2019 279
HTS_TST_POS Service Delivery Point (Community) Index Mod: 20-24, Male, Positive 2019 152
HTS_TST_POS Service Delivery Point (Community) Index Mod: 50+, Female, Positive 2019 428
HTS_TST_POS Service Delivery Point (Community) Index Mod: 50+, Male, Positive 2019 738
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive 2019 61
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive 2019 49
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive 2019 82
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive 2019 34
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive 2019 287
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive 2019 80
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive 2019 274
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive 2019 426
HTS_TST_POS Service Delivery Point (Community) Other: 15-19, Female, Positive 2019 185
HTS_TST_POS Service Delivery Point (Community) Other: 15-19, Male, Positive 2019 105
HTS_TST_POS Service Delivery Point (Community) Other: 20-24, Female, Positive 2019 247
HTS_TST_POS Service Delivery Point (Community) Other: 20-24, Male, Positive 2019 105
KP_MAT Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months 2019 229
KP_MAT Sex: Female 2019 29
KP_MAT Sex: Male 2019 200
KP_MAT Sum of Sex disaggregates 2019 229
KP_PREV By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 555
KP_PREV By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 4,999
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2019 5,554
PP_PREV 25-29, Female 2019 1,784
PP_PREV 25-29, Male 2019 10,342
PP_PREV 30-34, Female 2019 1,784
PP_PREV 30-34, Male 2019 7,845
PP_PREV 35-39, Female 2019 714
PP_PREV 35-39, Male 2019 713
PP_PREV 40-49, Male 2019 713
PP_PREV Age/sex: 15-19 Female 2019 865
PP_PREV Age/sex: 15-19 Male 2019 561
PP_PREV Age/sex: 20-24 Female 2019 1,784
PP_PREV Age/sex: 20-24 Male 2019 8,559
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2019 35,663
PP_PREV Sum of Age/Sex disaggregates 2019 11,769
PrEP_NEW 25-29, Female 2019 74
PrEP_NEW 25-29, Male 2019 10
PrEP_NEW 30-34, Female 2019 74
PrEP_NEW 30-34, Male 2019 10
PrEP_NEW 35-39, Female 2019 56
PrEP_NEW 35-39, Male 2019 5
PrEP_NEW 40-49, Female 2019 37
PrEP_NEW 40-49, Male 2019 5
PrEP_NEW Female 15-19 2019 37
PrEP_NEW Female 20-24 2019 72
PrEP_NEW Female 50+ 2019 19
PrEP_NEW Male 15-19 2019 5
PrEP_NEW Male 20-24 2019 10
PrEP_NEW Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2019 414
PrEP_NEW Other Key Populations 2019 415
TX_NEW 25-29, Female, Positive 2019 11
TX_NEW 25-29, Male, Positive 2019 44
TX_NEW 30-34, Female, Positive 2019 16
TX_NEW 30-34, Male, Positive 2019 67
TX_NEW 35-39, Female, Positive 2019 16
TX_NEW 35-39, Male, Positive 2019 94
TX_NEW 40-49, Female, Positive 2019 32
TX_NEW 40-49, Male, Positive 2019 140
TX_NEW By Age/Sex: 15-19 Female 2019 28
TX_NEW By Age/Sex: 15-19 Male 2019 10
TX_NEW By Age/Sex: 20-24 Female 2019 88
TX_NEW By Age/Sex: 20-24 Male 2019 26
TX_NEW By Age/Sex: 50+ Female 2019 7
TX_NEW By Age/Sex: 50+ Male 2019 52
TX_NEW By Key populations: People who inject drugs (PWID) 2019 635
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 635
TX_NEW Sum of Age/Sex disaggregates 2019 211
Cross Cutting Budget Categories and Known Amounts Total: $115,500
Gender: Gender Based Violence (GBV) $97,500
GBV Prevention
Implementation
Capacity building
Motor Vehicles: Purchased $18,000